USPTO serial 78411101
METAPHORE PHARMACEUTICALS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- SPRUILL, DARRYL M
- Law office
- TMO LAW OFFICE 112 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with METAPHORE PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Belinda A. Boyer
BELINDA A BOYER SONNENSCHEIN NATH & ROSENTHAL LLPPO BOX 061080WACKER DR STATION SEARS TWRCHICAGO, IL 60606-1080Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | (Based on Intent to Use) Chemical, biochemical, biological, biotechnological products and preparations not including agarose, namely free radical and reactive oxygen species catalyst products, namely, compounds that mimic the catalytic activity of superoxide dismutase, intended for the pharmaceutical industry and for the sciences, other than for medical or veterinary use; chemical, biochemical, biological, biotechnological products not including agarose, namely free radical and reactive oxygen species catalyst products, namely, compounds that mimic the catalytic activity of superoxide dismutase for laboratory analyses, other than for medical or veterinary use; biochemicals namely, free radical and reactive oxygen species catalysts for in vitro use; biochemicals not including agarose namely, free radical and reactive oxygen species catalyst precursors for in vitro use; biochemicals not including agarose namely, free radical and reactive oxygen species catalyst metabolites for in vitro use; and chemical reagents not including agarose for scientific or research use | ACTIVE | — |
| 005 | (Based on Intent to Use) Pharmaceutical preparations not including agarose for the treatment of pain, inflammation and inflammatory diseases, cancer, degenerative diseases including cartilage degeneration and nenrodegeneration, cardiovascular diseases, autoimmune diseases including arthritis, diseases of the skin and epidermis, ocular diseases, veterinary diseases; and chemotherapeutic preparations not including agarose for use in chemotherapy | ACTIVE | — |
| 042 | (Based on Use in Commerce) Technical consultation and research in biology, pharmacology, biology, biotechnology, pharmacy, and medicine, namely consultation and research in the biology, biotechnology, pharmacology and medicine of free radical and reactive oxygen species catalysts, catalyst precursors and catalyst metabolites not including agarose; providing information in the fields of biology, biotechnology, pharmacy, and medicine, namely providing information on the biology, biotechnology, pharmacology and medicine of free radical and reactive oxygen species catalysts, catalyst precursors and catalyst metabolites not including agarose all for research and development purposes; research and development of new products for others in the fields of pharmacy, biology and biotechnology, medicine and the sciences, namely research and development for others in the biology, biotechnology, pharmacology and medicine of free radical and reactive oxygen species catalysts, catalyst precursors and catalyst metabolites not including agarose; and laboratory research in the fields of biology, biotechnology, pharmacy, and medicine and the sciences, namely laboratory research in the biology, biotechnology, pharmacology and medicine of free radical and reactive oxygen species catalysts, catalyst precursors and catalyst metabolites not including agarose | ACTIVE | Jun 12, 2003 |
| 044 | (Based on Use in Commerce) Providing information in the fields of biology, biotechnology, pharmacy, and medicine, namely providing information on the biology, biotechnology, pharmacology and medicine of free radical and reactive oxygen species catalysts, catalyst constructs, catalyst precusors and catalyst metabolites not including agarose all for treatment and diagnosis purposes | ACTIVE | Jun 12, 2003 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Metaphore Pharmaceuticals, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named METAPHORE PHARMACEUTICALS
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 3, 2006 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 3, 2006 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 2, 2006 | GNCF | CONTINUATION OF FINAL REFUSAL E-MAILED | — |
| Apr 2, 2006 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Feb 15, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jan 30, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 30, 2006 | PAPER RECEIVED | — | |
| Jul 28, 2005 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 28, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 26, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 7, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 7, 2005 | FAXX | FAX RECEIVED | — |
| Dec 7, 2004 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2004 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 29, 2004 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2004 | NWAP | NEW APPLICATION ENTERED | — |